Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
estimated completion

Description

Summary

First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07265807 in participants with selected advanced or metastatic solid tumors.

Official Title

A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE-FINDING, PHARMACOKINETIC, SAFETY AND TOLERABILITY STUDY OF PF-07265807 IN PARTICIPANTS WITH SELECTED ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES

Keywords

Neoplasm Metastasis TAMK (TAM kinase) MER (mer proto-oncogene) MERTK (mer proto-oncogene tyrosine kinase) AXL (AXL receptor tyrosine kinase) AXL/MER selective kinase inhibitor PD-1 (programmed cell death protein 1) PD-L1 (programmed cell death ligand 1) immune modulator

Eligibility

You can join if…

Open to people ages 18 years and up

  • Participants who are intolerant or resistant to standard treatment for selected solid tumors
  • at least one measurable or non-measurable lesion, not previously irradiated, as defined by RECIST 1.1
  • ECOG Performance Status 0 or 1, 2 with approval
  • Adequate Bone Marrow Function
  • Adequate Renal Function
  • Adequate Liver Function
  • Resolved acute effects of any prior therapy

You CAN'T join if...

  • Known active uncontrolled or symptomatic CNS metastases
  • Major surgery within 6 weeks, radiation therapy within 4 weeks, systemic anti-cancer therapy within 2 week or 5 half-lives (4 weeks or 5 half-lives for antibody therapies or investigational drug(s) taken on another study) prior to study entry
  • Active or history of autoimmune disease requiring >10mg/day prednisone or other concurrent immunosuppressive therapy
  • Active, uncontrolled infection (controlled HBV, HCV, HIV/AIDS may be allowed) as defined in protocol
  • Retinal or other serious ophthalmic disorders as defined in protocol
  • Clinically significant cardiac disease as defined in protocol
  • Inability to consume or absorb study drug
  • Known or suspected hypersensitivity to PF-07265807
  • Prohibited concomitant medications as defined in protocol

Locations

  • UCI/Chao Family Comprehensive Cancer Center not yet accepting patients
    Orange California 92868 United States
  • Rocky Mountain Lions Eye Institute (RMLEI) not yet accepting patients
    Aurora Colorado 80045 United States
  • University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) not yet accepting patients
    Aurora Colorado 80045 United States
  • University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) not yet accepting patients
    Aurora Colorado 80045 United States
  • University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) not yet accepting patients
    Aurora Colorado 80045 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Pfizer
Links
To obtain contact information for a study center near you, click here.
ID
NCT04458259
Phase
Phase 1
Study Type
Interventional
Last Updated